1. Home
  2. SLXN vs GURE Comparison

SLXN vs GURE Comparison

Compare SLXN & GURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • GURE
  • Stock Information
  • Founded
  • SLXN 2008
  • GURE 2006
  • Country
  • SLXN Israel
  • GURE China
  • Employees
  • SLXN N/A
  • GURE N/A
  • Industry
  • SLXN
  • GURE Major Chemicals
  • Sector
  • SLXN
  • GURE Industrials
  • Exchange
  • SLXN NYSE
  • GURE Nasdaq
  • Market Cap
  • SLXN 7.3M
  • GURE 8.5M
  • IPO Year
  • SLXN N/A
  • GURE 1992
  • Fundamental
  • Price
  • SLXN $0.80
  • GURE $0.69
  • Analyst Decision
  • SLXN Strong Buy
  • GURE
  • Analyst Count
  • SLXN 1
  • GURE 0
  • Target Price
  • SLXN $5.00
  • GURE N/A
  • AVG Volume (30 Days)
  • SLXN 141.1K
  • GURE 2.0M
  • Earning Date
  • SLXN 08-21-2025
  • GURE 05-13-2025
  • Dividend Yield
  • SLXN N/A
  • GURE N/A
  • EPS Growth
  • SLXN N/A
  • GURE N/A
  • EPS
  • SLXN N/A
  • GURE N/A
  • Revenue
  • SLXN N/A
  • GURE $7,958,395.00
  • Revenue This Year
  • SLXN N/A
  • GURE N/A
  • Revenue Next Year
  • SLXN N/A
  • GURE N/A
  • P/E Ratio
  • SLXN N/A
  • GURE N/A
  • Revenue Growth
  • SLXN N/A
  • GURE N/A
  • 52 Week Low
  • SLXN $0.58
  • GURE $0.50
  • 52 Week High
  • SLXN $41.85
  • GURE $1.65
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • GURE 51.40
  • Support Level
  • SLXN N/A
  • GURE $0.66
  • Resistance Level
  • SLXN N/A
  • GURE $0.99
  • Average True Range (ATR)
  • SLXN 0.00
  • GURE 0.09
  • MACD
  • SLXN 0.00
  • GURE -0.00
  • Stochastic Oscillator
  • SLXN 0.00
  • GURE 30.23

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About GURE Gulf Resources Inc. (NV)

Gulf Resources Inc is a holding company engaged in the manufacture and trade of bromine and crude salt, and natural gas; manufactures and sells chemical products used in oil and gas field exploration, oil and gas distribution, oil field drilling, wastewater processing, papermaking chemical agents and inorganic chemicals, and manufactures and sells materials for human and animal antibiotics. It operates in four segments: Bromine, Crude Salt, Chemical Products and Natural Gas. It derives maximum revenue from the Bromine segment which is commonly used in brominated flame retardants, fumigants, water purification compounds, dyes, medicines and disinfectants.

Share on Social Networks: